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OBJECTIVES: To investigate whether oxidized low-density lipoprotein is a suitable predictor of peripheral arterial disease severity. 
The role of oxidized low-density lipoprotein in the pathogenesis of atherosclerosis has already been investigated. Its relevance as a 
predictor of the appearance and worsening of coronary arterial disease is also well known. However, the same is not true regarding 
peripheral arterial disease.
METHOD: Eighty-five consecutive patients with an ankle-brachial pressure index (ABPI) < 0.9 and the presence of either intermit-
tent claudication or critical lower leg ischemia were included. The plasma level of IgG autoantibodies against oxidized low-density 
lipoprotein was evaluated through an enzyme-linked immunosorbent assay. The results were categorized into quartiles according 
to the ankle-brachial pressure index (a marker of peripheral arterial disease severity), and significant differences were investigated 
with the Kruskal-Wallis test.
RESULTS: There was no significant difference between the quartiles for this population (p = 0.33). No correlation was found 
between the ankle-brachial pressure index and oxidized low-density lipoprotein levels in subjects with clinically evident peripheral 
arterial disease with a wide range of clinical manifestations.
CONCLUSIONS: Oxidized low-density lipoprotein is not a good predictor of peripheral arterial disease severity.
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INTRODUCTION
The importance of laboratory predictors of the severity 
of common diseases has been growing along with the 
increasing availability of early therapeutic approaches 
to prevent or minimize disease-related complications. 
Therefore, the incidence and severity of atherothrombotic 
complications could be significantly reduced if the 
patients at higher risk for these complications are properly 
anticipated. However, one of the foremost current challenges 
is identifying patients with a higher risk of a poor outcome 
before the appearance of complications. Having these 
patients identified would cause a major impact not only 
on the quality of life of individual subjects but also on 
the pharmacoeconomy of entire communities, since the 
allocation of resources would be more rational.
Many laboratory markers have been investigated to 
determine if they are predictive of an increased risk of 
atherosclerosis progression and the emergence of its 
complications. With regard to peripheral arterial disease 
(PAD), thrombomodulin blood levels, for example, were not 
significantly elevated in patients with critical limb ischemia 
in comparison to patients with intermittent claudication. 
Thus, thrombomodulin is not a good predictor of PAD 
worsening.1
Among the clinical and laboratory markers available, 
the ankle-brachial pressure index (ABPI) is a well-known 
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predictor of PAD worsening.2 A low ABPI was associated 
with an increased risk of cardiovascular events, including 
death, independent of metabolic syndrome and other major 
cardiovascular disease risk factors.3 Furthermore, Fowkes 
et al. recently demonstrated that ABPI determination may 
improve the accuracy of cardiovascular risk prediction beyond 
the one achieved when using the Framingham risk score.4
The value of oxidized low-density lipoprotein (oxLDL) 
as a predictor of atherothrombotic complications has also 
been investigated. OxLDL was associated with carotid 
intimal-media thickness, unstable plaques in the coronary 
and carotid arteries, impaired brachial and coronary 
endothelial function, and coronary artery disease.
Moreover, oxLDL was also associated with the presence, 
extent,and interim development of carotid and femoral 
atherosclerosis over a five-year period.
However, only limited data are available regarding a 
potential relationship between ABPI and plasma oxLDL 
levels in subjects with PAD.
Because ABPI is primarily a severity index of the 
peripheral arteries’ disease, we hypothesized that patients 
with lower ABPI would have higher plasma oxLDL levels 
than patients with higher ABPI.
The aim of the present study was to investigate such a 
correlation in patients with PAD.
METHODS
Population
Eighty-five consecutive patients with PAD from the 
Vascular Surgery Division of the Hospital das Clinicas of 
the University of São Paulo were included in this study. The 
inclusion criteria were an ABPI < 0.90 and the presence of 
either intermittent claudication or critical lower leg ischemia. 
Informed consent from all subjects was obtained before this 
trial.
Autoantibody plasma level evaluation
A blood sample was drawn from a vein in the arm of 
each subject after an eight-hour overnight fast. The plasma 
was isolated and stored for subsequent analysis after 
centrifugation at 2500 rpm and 4°C for 20 minutes.
The plasma level of IgG autoantibodies against oxLDL 
(from this point on mentioned just as oxLDL levels) was 
evaluated as previously described.5 In brief, an enzyme-
linked immunosorbent assay was used. The optical density 
of the samples was read in a photometric plate reader at 460 
nm. Each plate was calibrated against an internal control 
(total IgG with protein concentration of 0.116 µg/mL in 
phosphate-buffered saline [PBS]; pH 7.4; 0.05 M) and a 
blank PBS sample. Thus, the results for oxLDL levels are 
shown according to the following formula: (anti-oxLDL 
antibody – blank)/internal control.
Statistical analysis
The oxLDL levels were categorized into quartiles 
according to ABPI, and the Kruskal-Wallis test was used to 
investigate whether there was a significant difference among 
quartiles. The level of significance was set to 0.05.
RESULTS
Table 1 shows the demographic data of the sample 
population from this study. It shows the predominance of 
smoking and hypertension as risk factors for PAD, and also 
the higher incidence of the disease in males. The ABPI`s 
interquartile range is quite wide, depicting this sample is 
highly representative of the population of patients with PAD.
Table 2 depicts the median oxLDL levels per ABPI 
quartile. There seems to be no substantial variation in 
oxLDL levels among the different ABPI quartiles. 
The statistical analysis revealed that there is no 
significant difference in oxLDL level among the ABPI-based 
quartiles for this population (p = 0.33).
DISCUSSION 
Profiling patients for risk factors regarding peripheral 
arterial disease is a continuously ongoing process.6-10 
Table 1 - Demographic data of the sample population.
Mean age (years) 65.31±10.44
Proportion of males 65.88 %
ABPI* (median ± IQR†) 0.45 ± 0.63
Duration of PAD‡ (months) 24.88 ± 29.91
Proportion of smokers (any point in lifetime) 74.12 %
Proportion of diabetic patients 37.65 %
Proportion of hypertensive patients 61.18 %
OxLDL§ (median ± IQR) 0.18 ± 0.16
*
 ankle-brachial pressure index; † interquartile range; ‡ peripheral arterial 
disease; § oxidized low-density lipoprotein
Table 2 - Median oxLDL levels per ABPI quartile.
Quartile 1st 2nd 3rd 4th
ABPI* median 0 0.38 0.53 0.68
OxLDL† median 0.21 0.14 0.17 0.16
*
 ankle-brachial pressure index; † oxidized low-density lipoprotein
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Among the many studied markers of PAD worsening, 
oxLDL is earning increasing importance as evidence of its 
participation in atherogenesis has accumulated.
The development of atherosclerosis depends on a 
delicate balance between proinflammatory stimuli and anti-
inflammatory, anti-oxidative defense mechanisms.
A typical feature of atherosclerosis is the accumulation 
of oxidatively modified low-density lipoproteins within 
plaques, and these lipoproteins are hypothesized to 
contribute to the inflammatory state of atherosclerosis and 
to play a key role in its pathogenesis.
As low-density lipoproteins (LDL) traverses the 
subendothelial space, it becomes oxidized and may induce 
endothelial dysfunction, one of the earliest manifestations 
of atherosclerosis. Indeed, oxLDL levels correlate with 
the occurrence of endothelial dysfunction. Endothelial 
dysfunction improves following lipid-lowering therapy with 
apheresis or statins.11
Native, non-oxidized lipoproteins elicit no or only weak 
effects on the production of reactive oxygen species. On 
the other hand, oxidation of LDL increases its capacity 
to stimulate O2- formation, either through activating the 
lectin-like receptor LOX-112 or increasing the production 
and concentration of asymmetric dimethyl L-arginine.13 The 
latter is an endogenous inhibitor of nitric oxide synthase and 
increases oxidative stress.14
OxLDL-induced O2- accumulates at the site of 
inflammation within atherosclerotic plaques, in the 
direct vicinity of all cell types that are involved in the 
pathogenesis of the disease. Experimental data showed that 
this accumulation may lead to cell proliferation, hypertrophy, 
apoptosis,or necrosis, depending on the amount and duration 
of the exposure of the cells to oxLDL.15,16 Moreover, this 
accumulation may also inactivate nitric oxide17 and sensitize 
the contractile apparatus of the vessel wall, thus inducing 
vasoconstriction.18
OxLDL is not present in normal arteries. However, it 
is present in many types of lesions, including very early 
fetal aortic lesions that form in response to maternal 
hypercholesterolemia during gestation. OxLDL is present 
even before monocytes enter into the vessel wall, suggesting 
that LDL oxidation occurs a priori in atherogenesis.19
Unstable plaques in human carotid and coronary arteries 
are significantly enriched for oxLDL. Carotid plaques 
that were removed with endarterectomy and considered 
vulnerable and unstable plaques after pathology studies 
presented a much greater content of oxLDL than stable 
carotid plaques.20 Furthermore, another study showed that 
such content was significantly decreased after treatment with 
statins.21 In addition, oxLDL plasma levels correlate with the 
incidence of angiographically complex coronary plaques.22
The role of oxLDL as a marker or predictor 
of atherosclerotic involvement or atherothrombotic 
complications has already been assessed through some 
interesting studies. These studies show correlations of 
oxLDL plasma levels with morphologic and functional 
abnormalities, as well as with clinical outcomes.
In subjects with familial hyperlipidemia, elevated blood 
oxLDL and LDL-cholesterol levels were associated with 
increased carotid intimal-media thickness.23 In two other 
studies, elevated plasma oxLDL levels were associated with 
increased carotid intimal- media thickness in asymptomatic 
subjects whose relatives had familial hypercholesterolemia 
and also in asymptomatic middle-aged males.24,25
A strong correlation between endothelial function 
abnormalities and high plasma levels of oxLDL was also 
demonstrated with regard to the coronary and brachial 
arteries.26,27 OxLDL plasma levels were also independent 
predictors of coronary artery disease28 and were even 
stronger predictors than LDL and total cholesterol blood 
levels.29
Finally, a prospective case-control study in men showed 
that oxLDL plasma levels were higher in the patients who 
would later present cardiovascular events compared to those 
who sustained no such events in the future.30
Our results showed no correlation between the ABPI and 
oxLDL levels in subjects with clinically evident PAD with 
a wide range of clinical manifestations. This finding differs 
from the results of some other investigations.
A study involving apparently healthy, atherosclerosis-
free individuals, with ages ranging from 35 to 55 years, 
found an association between high oxLDL blood levels and 
the presence of plaques, or at least intimal thickening, in 
the femoral arteries.31 Another trial demonstrated that the 
oxidized phospholipids/apolipoprotein B ratio was strongly 
and significantly associated with the presence, extent and 
development of carotid and femoral atherosclerosis and 
predicted the presence of symptomatic cardiovascular 
disease.32 Taken together, these two studies show that 
elevated plasma oxLDL levels may either appear before the 
disease becomes clinically evident or be strong predictors of 
the worsening of the disease in the future.
Another key aspect when assessing the relevance oxLDL 
levels as a severity predictor is its timing. 
In this way, it was already observed that long-standing 
type 2 diabetic patients show a significant inverse correlation 
between the ABPI and plasma oxLDL levels; this correlation 
is not observed in recently diagnosed type 2 diabetic 
subjects.33
It is important to stress that the long-standing diabetic 
group mentioned above presented an ABPI of 0.86 ± 0.29 
(mean ± standard deviation), which is significantly higher 
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than the ABPI found in our population. The finding of a 
higher ABPI is a sign that some individuals of that group 
had no or very early atherosclerotic compromise, in sharp 
contrast with a substantial lower median ABPI found in our 
population.
 In our study, all the patients were in an advanced stage 
of PAD. Nonetheless, a wide range of clinical severities 
was observed within that population. Therefore, plasma 
oxLDL levels were assessed in patients with diverse degrees 
of severity. Even the patients with higher ABPI values 
presented a long-standing, clinically evident disease.
These results could indicate that plasma oxLDL levels 
may have a stronger impact in the early phase of the disease 
but not in the late phase, when PAD is already established.
Indeed, the work from Piarulli et al. demonstrated that 
plasma oxLDL levels were increased just among the long-
standing diabetes patients. Their finding may be because 
steady and prolonged metabolic abnormalities are required to 
furnish a favorable environment for LDL to be oxidized. The 
pathophysiologic processes that occur due to the presence 
of oxLDL in the arterial wall microenvironment take place 
long thereafter. By the time the atherosclerotic disease 
becomes evident, the role played by oxLDL may be much 
less important.
There is also evidence that plasma oxLDL levels is 
increased in acute coronary syndrome34 and that these 
increased levels may have a relationship with the severity 
and the timing of that ischemic event. Plasma oxLDL levels 
are higher in the acute phase of the myocardial ischemia 
and decrease gradually over time. In our population, no 
patient presented acute ischemia or sudden worsening of the 
underlying critical ischemia. It is possible that in such stable 
cases, with no plaque-related acute events, great changes in 
oxLDL levels are not present.
A limitation of our work is its cross-sectional design. 
Although this kind of approach may enable important 
inferences, a prospective longitudinal study may reach 
more robust conclusions. However, to our knowledge, 
this is the first study assessing the correlation between 
ABPI and plasma oxLDL levels in patients with clinically 
evident PAD, and thus this study provides insight into the 
importance of this marker.
CONCLUSION
In conclusion, there is no correlation between ABPI 
and the plasma levels of autoantibodies against oxLDL 
in patients with clinically evident PAD. OxLDL is not a 
good predictor of the worsening or severity of peripheral 
atherosclerosis.
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